目的 采用文献计量学方法分析类风湿关节炎相关间质性肺病（rheumatoid arthritis-associated interstitial lung disease，RA-ILD）治疗药物的研究现状和热点。方法 从Web of Science、PubMed、中国知识资源总库、万方和维普数据库中检索自建库至2025年2月10日药物治疗RA-ILD的文献。使用VOSviewer和CiteSpace软件对年度文献数量、高被引文献和期刊、国家和机构贡献、作者共现、关键词共现、关键词时间线、临床研究指标、基础实验指标以及具体用药情况进行可视化分析。结果 共纳入204篇英文文献和127篇中文文献，年度发文量整体呈上升趋势。英文文献发文最多的国家是美国，中、英文文献发文最多的机构分别为北京中医药大学和University of Modena and Reggio Emilia，发文最多的期刊分别为《风湿病与关节炎》和Rheumatology，发文最多的作者分别为李松伟和Sebastiani Marco。中、英文文献的高频关键词分别为肺功能、肺间质纤维化、间质性肺炎、环磷酰胺、雷公藤多苷片和mortality、idiopathic pulmonary-fibrosis、pneumonia、methotrexate、rituximab。有关化学药和生物药治疗RA-ILD的发文量大于中药，化学药中免疫抑制剂使用最多；中医药疗法中活血，补益肺、脾、肾和益气药使用最多。临床以肺部影像学、肺功能和血液指标检测为主要药效评价指标，基础实验研究开展比较薄弱，药效评估以肺组织形态学观察和纤维化标志物的检测为主要指标。结论 RA-ILD药物治疗当前以化学药和生物药治疗为主，以临床研究为主要研究类型；在研究热点方面，化学药和生物药研究主要侧重于死亡率、风险因素，比较关注药物的安全性，中医药研究侧重于治法和疗效。抗纤维化化学药、中医药，特别是中医药的基础研究将成为未来RA-ILD的研究趋势。

Objective To analyze the research status and hotspots concerning medications treatment for rheumatoid arthritis-related interstitial lung disease (RA-ILD) using bibliometric methods. Methods Literature on drug treatments for RA-ILD was retrieved from Web of Science, PubMed, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases, covering studies up to February 10, 2025. The VOSviewer and CiteSpace software were used to conduct visual analyses on the annual number of literatures, highly cited literatures and journals, national and institutional contributions, author co-occurrence, keyword co-occurrence, keyword timelines, clinical research indicators, basic experimental indicators, and specific drug usage statistics. Results A total of 204 English-language articles and 127 Chinese-language articles were included, showing an overall increasing trend in publication volume. The country with the highest number of English publications was the United States. The institutions with the highest publication output were the University of Modena and Reggio Emilia (Italy) for English articles, and Beijing University of Chinese Medicine (China) for Chinese articles. The journals with the most published articles were Rheumatism and Arthritis and Rheumatology. The most prolific authors were Marco Sebastiani for English articles and Songwei Li for Chinese articles. High-frequency keywords included “mortality, idiopathic pulmonary fibrosis, pneumonia, methotrexate and rituximab” in English literature, and “lung function, pulmonary interstitial fibrosis, interstitial pneumonia, cyclophosphamide and tripterygium glycosides tablet” in Chinese literature. The volume of publications on the treatment of RA-ILD with chemical drugs and biological agents exceeds that of traditional Chinese medicine (TCM). Among chemical drugs, immunosuppressants are the most frequently used. In TCM therapies, drugs for promoting blood circulation, tonifying the lung, spleen, and kidney, and replenishing qi are the most commonly employed. Clinically, pulmonary imaging, pulmonary function tests, and blood parameter detection serve as the primary indicators for evaluating drug efficacy. Basic experimental research in this field is relatively inadequate. In terms of efficacy assessment, lung tissue histological observation and the detection of fibrosis markers are the main indicators. Conclusion Currently, the pharmacological treatment of RA-ILD predominantly relies on chemical drugs and biological agents, with clinical research being the dominant research type. Regarding research hotspots, studies on chemical drugs and biological agents primarily focus on mortality rates and risk factors, with a particular emphasis on drug safety. In contrast, TCM research centers on therapeutic methods and efficacy. Anti-fibrotic chemical drugs and TCM, especially basic research in TCM, are expected to become the future research trends in RA-ILD.

G350;R285

国家自然科学基金项目（82204712）；国家自然科学基金项目（823301248）；国家自然科学基金项目（82274176）；国家自然科学基金项目（81974529）